ReviewJournal of human hypertension2014
A critical review of the evidence supporting aldosterone in the etiology and its blockade in the treatment of obesity-associated hypertension.
Review in Journal of human hypertension, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 23 citations in OpenAlex.
- Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association.Hypertension (Dallas, Tex. : 1979) · 2018Guideline
- Obesity and the diagnostic accuracy for primary aldosteronism.Journal of clinical hypertension (Greenwich, Conn.) · 2017Trial
- Rising Prevalence of Obesity and Primary Hyperaldosteronism: Co-incidence or Connected Circumstances Leading to Hypertension? A Narrative Review.Journal of general internal medicine · 2025Review
- Water intake, thirst, and copeptin responses to two dehydrating stimuli in lean men and men with obesity.Obesity (Silver Spring, Md.) · 2022Article
- High body fat percentage is associated with primary aldosteronism: a cross-sectional study.BMC endocrine disorders · 2020Article
- Obesity-related hypertension: a review of pathophysiology, management, and the role of metabolic surgery.Gland surgery · 2020Review
- Renal tubule insulin receptor modestly promotes elevated blood pressure and markedly stimulates glucose reabsorption.JCI insight · 2018Article
- Na+-sensitive elevation in blood pressure is ENaC independent in diet-induced obesity and insulin resistance.American journal of physiology. Renal physiology · 2016Article
- Serum Cortisol-to-Cortisone Ratio and Blood Pressure in Severe Obesity before and after Weight Loss.Cardiorenal medicine · 2015Article
- Cortisol dysregulation in obesity-related metabolic disorders.Current opinion in endocrinology, diabetes, and obesity · 2015Review
- Adipokines: another link between obesity and hypertension.Journal of human hypertension · 2015Article
- Metabolic syndrome in hypertensive patients: An unholy alliance.World journal of cardiology · 2014Review
- Renal sympathetic nervous system and the effects of denervation on renal arteries.World journal of cardiology · 2014Review
- The pathophysiology of hypertension in patients with obesity.Nature reviews. Endocrinology · 2014Review
Corrections and comments
- Commented on by
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Obesity is epidemic and is associated with increased blood pressure, which often manifests as treatment-resistant hypertension. Mineralocorticoids have been hypothesized to have a pathogenic role in human obesity-associated hypertension. In this review, we critically appraise the existing data regarding aldosterone in the pathophysiology and treatment of obesity-associated hypertension. We begin by reviewing the mechanisms by which obesity may increase mineralocorticoid activity. We then discuss human studies of plasma and urine aldosterone in obesity and with weight loss. From these studies, we conclude that aldosterone is often, but not always, mildly increased in obesity. Further study is needed to define circumstances in which aldosterone is increased in obesity. We discuss clinical studies in which measures of body size or weight were evaluated as potential predictors of response to mineralocorticoid receptor antagonists. In addition, we review three randomized, controlled clinical trials that exemplify a rigorous approach to determining the role of mineralocorticoid activity in a human disease. We propose that a similar clinical trial is warranted in order to definitively clarify the role of inappropriate mineralocorticoid activity in the etiology of human obesity-associated hypertension. Finally, we conclude that additional research is needed into the possible role of non-aldosterone mineralocorticoids in human obesity-associated hypertension.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.